home / stock / xoma / xoma quote
Last: | $25.51 |
---|---|
Change Percent: | -0.94% |
Open: | $25.9 |
Close: | $25.51 |
High: | $25.9 |
Low: | $25.41 |
Volume: | 7,231 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$25.51 | $25.9 | $25.51 | $25.9 | $25.41 | 7,231 | 05-17-2024 |
$25.66 | $24.98 | $25.66 | $26 | $24.97 | 10,736 | 05-16-2024 |
$24.71 | $25.67 | $24.71 | $26.29 | $24.71 | 11,920 | 05-15-2024 |
$25.59 | $25.68 | $25.59 | $25.88 | $24.7752 | 12,140 | 05-14-2024 |
$25.77 | $25.44 | $25.77 | $26.4 | $25.44 | 5,625 | 05-13-2024 |
$25.44 | $24.28 | $25.44 | $25.74 | $24.28 | 10,959 | 05-10-2024 |
$23.69 | $24.01 | $23.69 | $25.4 | $23.69 | 9,526 | 05-09-2024 |
$24.2 | $23.9814 | $24.2 | $24.78 | $23.9279 | 7,899 | 05-08-2024 |
$24.52 | $24.56 | $24.52 | $25.195 | $24.52 | 6,993 | 05-07-2024 |
$25.02 | $24.76 | $25.02 | $25.255 | $24.76 | 5,879 | 05-06-2024 |
$24.78 | $25.58 | $24.78 | $25.58 | $24.6 | 8,213 | 05-03-2024 |
$25.44 | $25.81 | $25.44 | $25.81 | $25 | 13,491 | 05-02-2024 |
$25.82 | $25.28 | $25.82 | $25.82 | $25.25 | 13,366 | 05-01-2024 |
$25.34 | $25.9191 | $25.34 | $26 | $25.0199 | 10,205 | 04-30-2024 |
$26.5 | $25.57 | $26.5 | $26.735 | $25.57 | 12,311 | 04-29-2024 |
$25.41 | $25.08 | $25.41 | $25.4972 | $25.08 | 6,127 | 04-26-2024 |
$25.36 | $25.55 | $25.36 | $26.75 | $25.2 | 6,783 | 04-25-2024 |
$25.64 | $26.14 | $25.64 | $26.14 | $25.515 | 8,219 | 04-24-2024 |
$26.09 | $26.48 | $26.09 | $26.79 | $25.82 | 11,780 | 04-23-2024 |
$25.82 | $25.25 | $25.82 | $26.5 | $25.25 | 7,314 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today that member...
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2 nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in ...
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in...